Exon skipping is a therapeutic approach using AONs to reframe dystrophin transcripts for DMD and is currently evaluated in clinical trials.11 2FPS AONs have shown unanticipated enhanced exon skipping in a model of spinal muscular atrophy due to recruitment of ILF2/3 proteins to the 2F/pre-mRNA duplex.13 For DMD, exon skipping is a desired feature, making 2FPS AONs potentially useful tools for reframing dystrophin transcripts. The gene discussed is ILF2; the disease is proximal spinal muscular atrophy.